Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 8/20 | 0.45 |
| ▸ | RAB9A | P51151 | 8/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12176559 | 1.00 | KMT2A (0.54) | KMT2ARXFP1USP2NPC1RAB9A | |
| SCHEMBL19151892 | 1.00 | KMT2A (0.54) | KMT2ARXFP1USP2NPC1RAB9A | |
| SCHEMBL24522239 | 1.00 | KMT2A (0.54) | KMT2ARXFP1USP2NPC1RAB9A | |
| SCHEMBL19130867 | 1.00 | KMT2A (0.54) | KMT2ARXFP1USP2NPC1RAB9A | |
| SCHEMBL12176367 | 0.91 | KMT2A (0.53) | KMT2ARXFP1USP2NPC1RAB9A | |
| SCHEMBL14959026 | 0.88 | KMT2A (0.54) | KMT2ARXFP1USP2NPC1RAB9A | |
| SCHEMBL18532597 | 0.88 | KMT2A (0.54) | KMT2ARXFP1USP2NPC1RAB9A | |
| SCHEMBL14960572 | 0.88 | KMT2A (0.54) | KMT2ARXFP1USP2NPC1RAB9A | |
| SCHEMBL12175990 | 0.88 | KMT2A (0.54) | KMT2ARXFP1USP2NPC1RAB9A | |
| SCHEMBL18532607 | 0.88 | KMT2A (0.53) | KMT2ARXFP1USP2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779576-B2 | Method of treating C3 glomerulopathy | CHEMOCENTRYX, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779576-B2 | Method of treating C3 glomerulopathy | CHEMOCENTRYX, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4015504-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3508477-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20190201388-A1 | METHOD OF TREATING C3 GLOMERULOPATHY | CHEMOCENTRYX, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20170202821-A1 | METHOD OF TREATING C3 GLOMERULOPATHY | CHEMOCENTRYX, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170114017-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170065604-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-03-09 | — | — | US | disclosed |
| US-9573897-B2 | C5AR antagonists | CHEMOCENTRYX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150141425-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8906938-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141425-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4442/4885RXFP1 911/4885USP2 3279/4885 |
| US-20170114017-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4442/4885RXFP1 911/4885USP2 3279/4885 |
| US-11779576-B2 | Method of treating C3 glomerulopathy | C3AR1, C5, C5AR1 | KMT2A 4638/4885RXFP1 3911/4885USP2 2253/4885 |
| US-20170202821-A1 | METHOD OF TREATING C3 GLOMERULOPATHY | C3AR1, C5, C5AR1 | KMT2A 4638/4885RXFP1 3911/4885USP2 2253/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4442/4885RXFP1 911/4885USP2 3279/4885 |
| US-20170065604-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | KMT2A 4510/4885RXFP1 892/4885USP2 3212/4885 |
| US-20190201388-A1 | METHOD OF TREATING C3 GLOMERULOPATHY | C3AR1, C5, C5AR1 | KMT2A 4638/4885RXFP1 3911/4885USP2 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.